Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: pain

U.S. Senator Reveals Results of Opioid Inquiry into Insys

Nate Raymond  |  September 7, 2017

BOSTON (Reuters)—Insys Therapeutics Inc sought to manipulate insurance payment approval for an opioid cancer pain drug called Subsys even if for inappropriate uses, according to a U.S. Senate report on the opioid crisis released on Wednesday. The report, released by Democratic Senator Claire McCaskill, said those efforts led to an Insys employee making misleading statements…

Filed under:Drug UpdatesLegal Updates Tagged with:Insys Therapeutics Incopioid crisisSubsys opioid drugU.S. Democratic Senator Claire McCaskillU.S. Senate report

High Prevalence of Kingella Kingae in Children with Joint Infections

Anne Harding  |  September 7, 2017

NEW YORK (Reuters Health)—Oropharyngeal carriage of Kingella kingae is strongly associated with osteoarticular infection in young children, a case-control study done from Canada and Switzerland shows. “Most of the kids who have osteoarticular infection with Kingella kingae will also have it in their throat, so if we do a throat swab, we can identify it…

Filed under:Conditions Tagged with:K. kingaeKingella kingaeoropharyngeal carriageosteoarticular infection

ACR/ARHP Makes Another Push to Repeal Medicare Therapy Caps

Gretchen Henkel  |  September 6, 2017

H.R. 807, Medicare Access to Rehabilitation Services Act of 2017, will be one of the key issues discussed when members of the ACR’s Government Affairs Committee (GAC) visit Capitol Hill Sept. 26 during the annual Advocates for Arthritis event. This bill—as well as its companion bill in the Senate, S. 253—is aimed at repealing the…

Filed under:Legislation & Advocacy Tagged with:Advocates for ArthritisH.R. 807Medicare Access to Rehabilitation Services Act of 2017Medicare therapy cap repeal

Arizona Accuses Insys of Fraudulent Opioid Marketing Scheme

Nate Raymond  |  August 31, 2017

(Reuters)—Arizona’s attorney general sued Insys Therapeutics Inc on Thursday, accusing the drugmaker of engaging in a fraudulent marketing scheme aimed at increasing sales of a fentanyl-based cancer pain medicine. The lawsuit by Arizona Attorney General Mark Brnovich in Maricopa County Superior Court in Phoenix comes during a series of federal and state investigations centered on…

Filed under:Drug UpdatesLegal Updates Tagged with:Arizona Attorney General Mark Brnovichfraudulent marketing schemeInsys Therapeutics Inclawsuitopioid crisisSubsys opioid drug

Opioid Use in U.S. RA Patients

Arthritis & Rheumatology  |  August 30, 2017

Nationally, opioid use and addiction are drawing increased scrutiny. An increase in the number of overdoses and addiction to heroin and prescription pain relievers in the past decade has been attributed in part to increased prescribing of opioids for the treatment of pain by physicians. National trends suggest the rate of opioid prescribing plateaued in…

Filed under:AnalgesicsConditionsDrug UpdatesResearch RheumRheumatoid Arthritis Tagged with:Arthritis & RheumatologyOpioid abuseOpioidsRAResearchRheumatoid Arthritis (RA)

New SLE Criteria Under Development: A Joint Effort of the ACR & EULAR

Thomas R. Collins  |  August 25, 2017

MADRID—Systemic lupus erythematosus (SLE) experts in North America and Europe are working together to refine the classification system for the disease, with the goal of producing a new set of criteria that is simpler to use and more scientifically rigorous than any classification approach previously published, speakers involved with the process said at the 2017…

Filed under:ConditionsEULAR/OtherMeeting ReportsSystemic Lupus Erythematosus Tagged with:Classification CriteriacriteriaEULARsystemic lupus erythematosus (SLE)

Flimsy Evidence Behind Many FDA Approvals

Will Boggs, MD  |  August 21, 2017

(Reuters Health)—Many drugs granted accelerated approval by the U.S. Food and Drug Administration (FDA) lack clear evidence of safety and effectiveness, and the same is true for most high-risk medical devices, according to two new reports in JAMA, online Aug. 15. The Accelerated Approval pathway makes potentially promising investigational medicines available for use before the…

Filed under:Drug Updates Tagged with:drug developmentDrug SafetyFDAFood and Drug Administrationhigh-risk medical devicesmedical deviceMedicationU.S. Food and Drug Administration

Some Jobs Tied to Higher Risk of RA

Lisa Rapaport  |  August 18, 2017

(Reuters Health)—Workers exposed to airborne toxins may have an elevated risk of developing rheumatoid arthritis (RA), an immune system disorder that causes debilitating swelling and pain in the joints, a Swedish study suggests. Among men, bricklayers, concrete workers and electricians had at least twice the risk of RA they would have in certain other occupations,…

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:Arthritis Care & Researchenvironmentenvironmental factorjobRheumatoid Arthritis (RA)

S.C. Sues Purdue, Maker of OxyContin, Over Deceptive Marketing

Nate Raymond  |  August 16, 2017

(Reuters)—On Tuesday, South Carolina sued Purdue Pharma LP, becoming the latest state or local government to accuse the OxyContin maker of deceptive marketing practices that have contributed to a national opioid addiction epidemic. The lawsuit by South Carolina Attorney General Alan Wilson, filed in Richland County Court of Common Pleas in Columbia, accuses the company…

Filed under:Drug UpdatesLegal Updates Tagged with:AddictionLegalOpioid abuseopioid crisisopioid drug probeopioid epidemicOpioids

Calcium Crystal Deposition in Rheumatic Diseases: Mechanisms & Evaluation of Calcium Crystal Deposits Explored

Thomas R. Collins  |  August 15, 2017

MADRID—Calcification in osteoarthritis (OA) involves a series of pathways and interactions that feed off each other in a process that bears some resemblance to the transformation of cartilage to bone that takes place in the embryonic stage of human development, a researcher said here at the 2017 Annual European Congress on Rheumatology (EULAR). “My hypothesis…

Filed under:ConditionsEULAR/OtherMeeting ReportsOsteoarthritis and Bone Disorders Tagged with:cartilageEULARimagingosteoarthritis (OA)TendinopathyUltrasound

  • « Previous Page
  • 1
  • …
  • 130
  • 131
  • 132
  • 133
  • 134
  • …
  • 243
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences